A Review of Pharmaceutical and Clinical Studies of the Cholesterol-Lowering Drug PCSK9 Inhibitor Inclisiran

Ziyi Gao; Zhuodong Li; Yuxuan Gu; Yunfei Bai; Xiangjian Xiao

doi:10.18063/apm.v0505

ARTICLE

Volume 10,Issue 3

All Issues

Submit to JMDS

Cite this article

Download

Citations

115

Views

A Review of Pharmaceutical and Clinical Studies of the Cholesterol-Lowering Drug PCSK9 Inhibitor Inclisiran

Ziyi Gao¹, Zhuodong Li², Yuxuan Gu¹, Yunfei Bai³, Xiangjian Xiao^4*

Show Less

¹ Graduate School, Hebei North University, Hebei Zhangjiakou 075132, China

² Department of Cardiology, Hebei General Hospital, Hebei Shijiazhuang 050057, China

³ Graduate School, North China University of Science and Technology, Hebei Tangshan 063000, China

⁴ Hebei Key Laboratory of Brain Network and Cognitive Disorders, Hebei General Hospital, Hebei Shijiazhuang 050057, China

JMDS 2025 , 10(1), 28–33; https://doi.org/10.18063/apm.v0505

© 2025 by the Author(s). Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Abstract

Hypercholesterolemia can lead to atherosclerosis, which in turn can cause a range of cardiovascular and cerebrovascular diseases. As the first drug approved by the US Food and Drug Administration in 2021 to lower low-density lipoprotein cholesterol through siRNA therapy, inclisiran’s sustained potent lipid-lowering effect and safety profile make it a promising treatment option for dyslipidemia. This article reviews the latest research progress on the mechanism of action, pharmacokinetic properties, efficacy, and safety of inclisiran. It also briefly explains its unique clinical administration method, aiming to provide a reference for the clinical use of inclisiran.

Keywords

Inclisiran

Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors

siRNA therapy

Low-density lipoprotein cholesterol

References

1. Joint Committee for the Revision of Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2016). Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2016 Revision). Chinese Circulation Journal, 31(10), 937–950.
2. Bi, L. (2022). A Simulation Study on the Epidemiological Characteristics of Blood Lipids, the Application Status of Statins, and the Burden of Lipid-Lowering Treatment in Chinese People. Thesis, Chinese Academy of Medical Sciences.
3. Chinese Cardiovascular Health and Disease Report Writing Team (2022). Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary. Chinese Circulation Journal, 37(6), 553–578.
4. Joint Expert Committee for the Revision of Chinese Guidelines for Blood Lipid Management (2023). Chinese Guidelines for Lipid Management (2023). Chinese Circulation Journal, 38(3), 237–271.
5. Dong, Z. J., Xue, C. J., Qiu, X. J., et al. (2023). Clinical Comprehensive Evaluation of Statins in the Treatment of Dyslipidemia. Chinese Journal of Hospital Pharmacy, 43(19), 2179–2186.
6. Jin, Z. Y., Luo, M., Tian, Y., et al. (2021). Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors on Familial Hypercholesterolemia: A Systematic Review. Chinese Journal of Hospital Pharmacy, 41(8), 833–839.
7. Nelson, A. J., Puri, R., Brennan, D. M., et al. (2020). C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights from GLAGOV. American Journal of Preventive Cardiology, 3, 100091.
8. Banerjee, Y., Stoian, A. P., Cicero, A. F. G., et al. (2022). Inclisiran: A Small Interfering RNA Strategy Targeting PCSK9 to Treat Hypercholesterolemia. Expert Opinion on Drug Safety, 21(1), 9–20.
9. Lamb, Y. N. (2021). Inclisiran: First Approval. Drugs, 81(3), 389–395.
10. Urban, D., Pöss, J., Böhm, M., et al. (2013). Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis. Journal of the American College of Cardiology, 62(16), 1401–1408.
11. Merćep, I., Friščić, N., Strikić, D., et al. (2022). Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9 – A Narrative Review. Cardiovascular Therapy, 2022, 8129513.
12. Barale, C., Melchionda, E., Morotti, A., et al. (2021). PCSK9 Biology and Its Role in Atherothrombosis. International Journal of Molecular Sciences, 22(11), 5880.
13. Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021). The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently? Current Atherosclerosis Reports, 23(8), 40.
14. German, C. A., & Shapiro, M. D. (2020). Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs, 34(1), 1–9.
15. Tomlinson, B., Chow, E., Chan, P., et al. (2021). An Evaluation of the Pharmacokinetics of Inclisiran in the Treatment of Atherosclerotic Cardiovascular Disease. Expert Opinion on Drug Metabolism & Toxicology, 17(12), 1353–1361.
16. Wright, R. S., Collins, M. G., Stoekenbroek, R. M., et al. (2020). Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clinic Proceedings, 95(1), 77–89.
17. Kallend, D., Stoekenbroek, R., He, Y. L., et al. (2022). Pharmacokinetics and Pharmacodynamics of Inclisiran, a Small Interfering RNA Therapy, in Patients with Hepatic Impairment. Journal of Clinical Lipidology, 16(2), 208–219.
18. Zijlstra, L. E., Trompet, S., Mooijaart, S. P., et al. (2020). Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. Mayo Clinic Proceedings, 95(1), 12–14.
19. Ray, K. K., Landmesser, U., Leiter, L. A., et al. (2017). Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine, 376(15), 1430–1440.
20. Ray, K. K., Stoekenbroek, R. M., Kallend, D., et al. (2019). Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-Up of the ORION-1 Randomized Clinical Trial. JAMA Cardiology, 4(11), 1067–1075.
21. Leiter, L. A., Teoh, H., Kallend, D., et al. (2019). Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Diabetes Care, 42(1), 173–176.
22. Raal, F. J., Kallend, D., Ray, K. K., et al. (2020). Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. The New England Journal of Medicine, 382(16), 1520–1530.
23. Landmesser, U., Haghikia, A., Leiter, L. A., et al. (2021). Effect of Inclisiran, the Small-Interfering RNA Against Proprotein Convertase Subtilisin/Kexin Type 9, on Platelets, Immune Cells, and Immunological Biomarkers: A Pre-Specified Analysis from ORION-1. Cardiovascular Research, 117(1), 284–291.
24. Jahangir, A., Sahra, S., Krzyzak, M. (2021). Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists. Cureus, 13(7), e16664.
25. Ray, K. K., Wright, R. S., Kallend, D., et al. (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine, 382(16), 1507–1519.
26. Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., et al. (2023). Long-Term Efficacy and Safety of Inclisiran in Patients with High Cardiovascular Risk and Elevated LDL Cholesterol (ORION-3): Results from the 4-Year Open-Label Extension of the ORION-1 Trial. Lancet Diabetes Endocrinology, 11(2), 109–119.
27. Luo, Z., Huang, Z. J., Sun, F., et al. (2023). The Clinical Effects of Inclisiran, a First-in-Class LDL-C Lowering siRNA Therapy, on the LDL-C Levels in Chinese Patients with Hypercholesterolemia. Journal of Clinical Lipidology, 17(3), 392–400.
28. Four Alliances to Promote High-Quality Development and Full-Course Care (2023-09-21).
29. Wright, R. S., Ray, K. K., Raal, F. J., et al. (2021). Pooled Patient-Level Analysis of Inclisiran Trials in Patients with Familial Hypercholesterolemia or Atherosclerosis. JACC: Journal of the American College of Cardiology, 77(9), 1182–1193.
30. Wołowiec, Ł., Osiak, J., Wołowiec, A., et al. (2023). Inclisiran - Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9. Pharmaceutics, 15(2), 323.
31. Al Shaer, D., Al Musaimi, O., Albericio, F., et al. (2024). 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 17(2), 243.

Conflict of interest

The authors declare no conflict of interest.

Previous article in this issue

Next article in this issue